Maybe health systems should put more energy into providing #ObesityCare and less into #screening people out of getting it.
https://conscienhealth.org/2023/09/rationalizing-denial-of-care-for-obesity/

While people needing #access to #ObesityCare struggle, health insurers and pharma find ways to rationalize the harm that flows from their economic interests. Unsurprising, unacceptable and indefensible.
https://conscienhealth.org/2023/09/pricing-insurance-and-bias-driving-disparities-in-obesity/

Health systems and #CulturalBias have built an almost impenetrable wall around #ObesityCare. Nine out of ten Rx's for #ObesityMeds never get filled says a new study in JMCP.
https://conscienhealth.org/2023/08/surprise-most-prescriptions-for-obesity-meds-are-never-filled/

For wealthy and well-insured U.S. patients, exorbitant #prices for #GLP1 meds are no problem. They pay the high price or their gold-plated health insurance takes care of it. But here's a question to ponder. Should #ObesityCare be a #luxury? https://conscienhealth.org/2023/08/high-u-s-drug-prices-high-obesity-rates-twisted-economics/

Our friend @NeilFlochMD is right on the mark when he says GLP-1 meds will not spell the demise of #MetabolicSurgery. More likely, they will usher in an age of more comprehensive #ObesityCare. https://conscienhealth.org/2023/08/surgery-plus-a-glp-1-one-plus-one-equals-three/

Who was first in line to enroll in the SELECT study to prevent heart attacks, strokes, and deaths in obesity with semaglutide? White men. This offers a hint about #disparities in #access to #ObesityCare.
https://conscienhealth.org/2023/08/an-issue-of-disparities-embedded-in-the-select-trial/

When headlines saying #semaglutide #SavesLives collide with employees hearing their #HealthInsurance is cutting them off from it and Novo Nordisk saying it will be next year before they make enough, there's definitely bedlam in #ObesityCare.
https://conscienhealth.org/2023/08/obesity-care-bedlam-but-no-worries/

Topline results of the #SELECT study from Novo Nordisk today show #semaglutide that treating #obesity with this drug prevents cardiovascular deaths, heart attacks, and strokes. This news marks the start of a sea change in #ObesityCare.
https://conscienhealth.org/2023/08/huge-news-semaglutide-cuts-deaths-cv-events-in-obesity/

How long must we wait for the walls that block most people from #ObesityCare to come tumbling down? Payers, the public, and makers of these drugs all bear responsibility for building these walls.
https://conscienhealth.org/2023/07/building-and-busting-walls-around-obesity-medicines/

One of the biggest landmark studies ever in #ObesityCare has come to an end and soon we will get the results. Will it be important? Yes. Will people fuss about the implications? We are certain of it.
#SELECT #Semaglutide
https://conscienhealth.org/2023/07/get-ready-to-argue-about-the-select-outcomes-study/

Shortages of #GLP1 medicines are growing worse. Novo Nordisk says "many patients will have difficulty filling #Saxenda prescriptions for the remainder of 2023 and beyond."
Was this foreseeable? Or is #ObesityCare for the few and the wealthy all we get?
https://conscienhealth.org/2023/07/glp-1-medicines-constrained-supply-high-prices-low-access/

As Matthias Tschöp accepted the Banting Medal for Scientific Achievement yesterday at #AAD2023, it was hard to miss the fact his work is bringing us into a golden age for #ObesityCare through stunning #innovation in medicine.
https://conscienhealth.org/2023/06/ada2023-a-golden-age-of-obesity-medicine/

This week marks big progress in Connecticut for #equity in #access to #ObesityCare. Thanks to Governor Ned Lamont for signing it into law and to Neil Floch & OAC advocates for the persistent hard work to make it happen.
https://conscienhealth.org/2023/06/persistent-pursuit-of-access-to-obesity-care/

What would happen if we stopped telling ourselves #ObesityCare is too costly and futile? A new analysis in the Journal of Medical Economics gives us a clue.
#CantNeverCould
https://conscienhealth.org/2023/06/grasping-obesity-care-costs-and-consequences/

“If you can’t be too rich or too thin, it turns out, you might have to be rich to be thin. The racial disparities – in obesity and access – make matters even worse.”
We need to talk – about #disparities and access to #ObesityCare.
https://conscienhealth.org/2023/06/privilege-stigma-and-better-obesity-care/

Big #disruptions are hitting #ObesityCare. They're uncomfortable and will get even more so. Along the way hazards will pop up, like #CompoundedSemaglutide. The U.S. Food and Drug Administration and pharma companies like Novo Nordisk and Eli Lilly and Company must get this right.
https://conscienhealth.org/2023/06/disruption-discomfort-and-hazards-in-obesity/

Once, innovators and providers ran from #ObesityCare. But now, better medicines are making the potential for making money on this obvious, so greed is prompting competition, which in turn may bring down #costs. Keep your eye on #HealthOutcomes.
https://conscienhealth.org/2023/05/greed-versus-health-and-obesity-care/

First it was #bariatric or weight loss #surgery. Then it became #metabolic and bariatric surgery. Maybe it's time to drop the confusing "bariatric" label. Because metabolic surgery has an enduring role to play in #ObesityCare.
https://conscienhealth.org/2023/05/goodbye-bariatric-hello-metabolic-surgery/

At #AACE2023 yesterday, Dr. Karl Nadolsky led in presenting and publishing a new consensus on #WeightBias in #ObesityCare. Honored to be an author, along with a host of other talented experts.
https://conscienhealth.org/2023/05/endocrinologists-prioritize-stigma-in-obesity-care/

Folks who tell us #affordable, #accessible, #ObesityCare is impossible are getting on our nerves. We can do this. We've done it before.
https://conscienhealth.org/2023/05/paying-for-innovation-in-obesity-care/